Dr. Azahari bin Kasbollah currently serves as a Research Officer Grade Q52M at the Malaysian Nuclear Agency, a position he has held since 2002. At the Malaysian Nuclear Agency he is responsible for the planning and implementation of research projects and development in the field of nuclear medicine, namely radioisotope and radiopharmaceutical research. As Project Head, he manages the upgrading works of the Nuclear Medicine Radioisotope Production Facility at the Medical Technology Division (BTP), as well as a collaborative research project with the National Cancer Institute (IKN) titled “Development of Samarium-153 EDTMP for Bone Palliative Treatment.” He also oversees the planning and implementation of activities related to GMP (Good Manufacturing Practice) Quality Management Process at the Medical Technology Division. Furthermore, he supervises and monitors the production of the Nuclear Medicine radioisotopes Iodine-131 dan Iridium-192 capsules.
Dr. bin Kasbollah has obtained a BSc (Hons) in Industrial Chemistry in 1998 and MSc in Synthetic Chemistry in 2002 from the Putra University in Malaysia. He earned his PhD in Medical Radiation Science in 2014 at the RMIT University in Victoria, Australia. He further posseses a qualification as a Graduate Technologist (Nuclear & Radiological Technology) from the Malaysian Technology Board.